After 20-month hold, FDA drops resistance to fecal pooling, clears MaaT to run pivotal trial

Twenty months after being rocked by a clinical hold, MaaT Pharma has finally received the green light from the FDA to run a phase 3 trial of its pooled fecal therapy in gastrointestinal acute graft-versus-host disease (GvHD) patients in the U.S.